U.S. Asthma Treatment Market Revenue to Attain USD 12.86 Bn by 2033

04 Dec 2024

Share :

Table of Content

1. U.S. Asthma Treatment Market Revenue and Trends 2023 to 2033 2. Market Overview  3. Report Highlights of the U.S. Asthma Treatment Market 4. U.S. Asthma Treatment Market Trends 5. U.S. Asthma Treatment Market Coverage 6. Market News

U.S. Asthma Treatment Market Revenue and Trends 2023 to 2033

The U.S. asthma treatment market revenue surpassed USD 11.04 billion in 2024 and is predicted to attain around USD 12.86 billion by 2033 with a CAGR of 1.73% during the forecast period. The increasing prevalence of asthma, developments of smart or digital inhalers, and increasing awareness regarding health are expected to drive the U.S. asthma treatment market during the forecast period.

Market Overview 

Asthma is a chronic respiratory condition caused by inflammation and narrowing of the airways. It also leads to breathing difficulty, coughing, whistling, and shortness of breath. It affects daily activities and results in life-threatening asthma attacks, also known as asthma exacerbation. Symptoms worsen in situations like exercise-induced asthma by cold or dry air. Irritants like chemical fumes, dust, gases, and airborne allergens such as mold spores, pollen, cockroach waste, or dry skin and dried saliva around the mouth cause asthma. With increasing instances of asthma, the demand for effective asthma treatment is rising in the U.S. The widespread availability of bronchodilators is likely to boost the market.

One of the major factors boosting market growth is the rising R&D to accelerate the development of effective asthma medications. Rising healthcare expenditures and increasing awareness regarding asthma management also contribute to market expansion. Furthermore, the rise in the development of biologic drugs, especially monoclonal antibodies such as mepolizumab, omalizumab, and dupilumab, that enhance the immune system and help manage symptoms drive the growth of the market. 

The demand for personalized medicine involving genetic testing and biomarker identification has the potential to fuel the market for U.S. asthma treatment. Furthermore, the rise in popularity of telemedicine for asthma management, which helps patients consult with healthcare professionals for routine checkups and medication prescriptions, coupled with the rising awareness of self-care and medication, is fueling market growth. Technological advancements have also led to the development of advanced therapeutic approaches, further bolstering the market.

Report Highlights of the U.S. Asthma Treatment Market

• By medication, the long-term control medication segment held the largest share of the market in 2023. This is mainly due to the increasing prevalence of asthma. Doctors advise asthma patients to take long-term controller medicines daily regardless of symptoms to reduce future risk. On the other hand, the quick-relief medication segment is expected to grow rapidly in the coming years. Quick-relief medications are used to treat acute asthma symptoms like wheezing, shortness of breath, chest tightness, and coughing. They are used in asthma attacks that are not very serious or intermittent asthma, which occurs twice a week or less with symptoms not more than twice a month.
• By route of administration, the inhalers segment dominated the market with the largest share in 2023, as they are most commonly used and effective in treating asthma. Moreover, technological advancements led to the development of smart inhalers with integrated digital technology that help track medication usage, set reminders, and offer proper asthma management plans, fueling segmental growth.
• By adjunct therapy, the LABA (long-acting beta antagonists) segment led the market in 2023. The widespread availability of bronchodilators that have a longer duration of action bolstered the segment. They are only used as add-on medication to prevent the symptoms.
• By distribution channel, the retail pharmacies and drug stores segment dominated the market in 2023. This is mainly due to the easy availability of prescription as well as over-the-counter drugs.

U.S. Asthma Treatment Market Trends

• Rising Air Pollution: Cold temperatures and rising nitrogen dioxide emissions create a risk of developing asthma among children and adults. Moreover, rising air pollution led to serious life-threatening chronic respiratory conditions that could affect the lives of individuals, driving the demand for asthma treatment. For instance, according to the report of the U.S. Environmental Protection Agency, nearly 102 million people in the U.S. live in areas with poor air quality, and climate-driven changes, including temperature and precipitation, are expected to increase the ground-level ozone and particulate matter, leading to exposure of the pollutants and causing health problems like respiratory and heart disease.
• Increasing Prevalence of Asthma: With the changing lifestyles of individuals, the instance of asthma is increasing in the U.S. In addition, asthma has also been recognized as a disorder in which psychological elements play a significant role, as emotional stress can trigger asthma and affect patients' mental health, which can trigger the symptoms. Depressive disorders are also common among people with asthma, boosting the growth of the market.
• Rising Use of Biologics: Biologics are drugs derived from natural sources like microorganisms, plants, or animals that target specific cells in the human body and disturb the process, contributing to inflammation and asthma symptoms. The use of biologics helps reduce the need for oral steroids and improves the quality of life of asthmatic patients.
• Growing FDA Approvals and Government Initiatives: The rising FDA approvals of new drugs create immense opportunities in the U.S. asthma treatment market. Moreover, rising government initiatives to accelerate the development of novel drugs and investments in research and development fuel market growth. For instance, the CDC's National Asthma Control Program (NACP) helps millions of people with asthma in the U.S. gain control over their disease. NACP currently funds 29 programs to improve asthma control services' reach, quality, and effectiveness and reduce asthma morbidity, mortality, and disparities.

U.S. Asthma Treatment Market Coverage

Market News

• In March 2024, ChestPal Ltd. launched ChestPal Pro, the next-generation digital stethoscope, in the U.S. for healthcare practitioners. This stethoscope is clinically backed to detect, classify, record, and share crackles and wheezes, including the conversion of lung sounds to visual spectrograms.
• In July 2023, Viatris Inc. launched Breyna (budesonide and formoterol fumarate dihydrate) inhalation aerosol. This generic version of AstraZeneca’s Symbicort, approved by the U.S. Food and Drug Administration, is indicated for certain patients with asthma or chronic obstructive pulmonary disease.

Market Segmentation

By Medication

• Quick-relief Medication
• Long-term Control Medication

By Route of Administration

• Inhalers
• Prefilled Syringes/Vials
• Others

By Adjunct Therapy

• LAMA (long-acting muscarinic antagonists)
• LABA (long-acting beta antagonists)
• Others

By Distribution Channel

• Online Pharmacies
• Hospital Pharmacies
• Retail pharmacies and Drug Stores

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 804 441 9344